No Data
No Data
No Data
No Data
No Data
Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
TipRanksMay 1 19:55
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Not Doing Enough For Some Investors As Its Shares Slump 26%
Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares have had a horrible month, losing 26% after a relatively good period beforehand. Longer-term shareholders will rue the drop in the share price, since
Simply Wall StApr 26 18:06
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
- Spotlight on new, second-generation, TRACER-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer's disease and
Voyager TherapeuticsApr 22 12:00
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
TipRanksApr 17 17:07
Selection Of The Development Candidate Triggered A $3M Milestone Payment To Voyager, Which The Company Expects To Receive In Q2 Of 2024
Selection Of The Development Candidate Triggered A $3M Milestone Payment To Voyager, Which The Company Expects To Receive In Q2 Of 2024
BenzingaApr 16 19:12
Voyager Therapeutics And Neurocrine Biosciences Expect To File An FDA Investigational New Drug Application For GBA1 Program Candidate In 2025
Voyager Therapeutics And Neurocrine Biosciences Expect To File An FDA Investigational New Drug Application For GBA1 Program Candidate In 2025
BenzingaApr 16 19:07
No Data
No Data